ESAs And Transfusions In Dialysis Patients: Watching For The Tipping Point

A study from the U.S. Renal Data System contributes to concerns that decreasing use of erythropoiesis-stimulating agents like Amgen’s Epogen in dialysis patients can lead to a significant increase in the need for blood transfusions.